Evidence map›Paper›PMID 26858248›Full record

ArticleThe Journal of biological chemistry2016

Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase.

Haoling Qi, Sudhakaran Prabakaran, François-Xavier Cantrelle, Béatrice Chambraud, Jeremy Gunawardena, Guy Lippens, Isabelle Landrieu

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 65 citations in OpenAlex.

  1. Analytical chemistry · 2026
    Article
  2. Review
  3. Article
  4. GSK3β phosphorylation catalyzes the aggregation of tau into Alzheimer's disease-like filaments.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The structure and phase of tau: from monomer to amyloid filament.Cellular and molecular life sciences : CMLS · 2021
    Review
  17. Review
  18. Article
  19. NMR Studies of Tau Protein in Tauopathies.Frontiers in molecular biosciences · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Haoling QiFrom Lille University, CNRS UMR8576, F-59000 Lille, France.
Sudhakaran PrabakaranDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, and.
François-Xavier CantrelleFrom Lille University, CNRS UMR8576, F-59000 Lille, France.
Béatrice ChambraudINSERM UMR1195 Paris SUD University, Le Kremlin Bicêtre 94276, France.
Jeremy GunawardenaDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, and.
Guy LippensFrom Lille University, CNRS UMR8576, F-59000 Lille, France.ORCID http://orcid.org/0000-0002-8236-0901
Isabelle LandrieuFrom Lille University, CNRS UMR8576, F-59000 Lille, France, isabelle.landrieu@univ-lille1.fr.
Centre National de la Recherche Scientifique · FRHarvard University · USUniversité Paris-Sud · FR

Funding

Complex Dynamics in Multisite PhosphorylationR01GM081578 · NIGMS · HARVARD MEDICAL SCHOOL · PI GUNAWARDENA, JEREMY · 2008 to 2011
$1.4M
NIGMS NIH HHS R01 GM081578
6 · The paper itself

Abstract

Tau neuronal protein has a central role in neurodegeneration and is implicated in Alzheimer disease development. Abnormal phosphorylation of Tau impairs its interaction with other proteins and is associated with its dysregulation in pathological conditions. Molecular mechanisms leading to hyperphosphorylation of Tau in pathological conditions are unknown. Here, we characterize phosphorylation of Tau by extracellular-regulated kinase (ERK2), a mitogen-activated kinase (MAPK) that responds to extracellular signals. Analysis ofin vitrophosphorylated Tau by activated recombinant ERK2 with nuclear magnetic resonance spectroscopy (NMR) reveals phosphorylation of 15 Ser/Thr sites.In vitrophosphorylation of Tau using rat brain extract and subsequent NMR analysis identifies the same sites. Phosphorylation with rat brain extract is known to transform Tau into an Alzheimer disease-like state. Our results indicate that phosphorylation of Tau by ERK2 alone is sufficient to produce the same characteristics. We further investigate the mechanism of ERK2 phosphorylation of Tau. Kinases are known to recognize their protein substrates not only by their specificity for a targeted Ser or Thr phosphorylation site but also by binding to linear-peptide motifs called docking sites. We identify two main ERK2 docking sites in Tau sequence using NMR. Our results suggest that ERK2 dysregulation in Alzheimer disease could lead to abnormal phosphorylation of Tau resulting in the pathology of the disease.

Indexed as

Alzheimer DiseaseAmino Acid MotifsAnimalsExtracellular Signal-Regulated MAP KinasesHumansNuclear Magnetic Resonance, BiomolecularPhosphorylationProtein Structure, TertiaryRatstau ProteinsExtracellular Signal-Regulated MAP KinasesMapt protein, rattau ProteinsAlzheimer diseaseextracellular signal-regulated kinase (ERK)nuclear magnetic resonance (NMR)protein phosphorylationprotein-protein interactionTau protein (Tau)

Identifiers

PMID26858248
PMCPMC4817198
OpenAlexW2300529250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.